Early risk screening for diabetes and heart disease in Ascoli Piceno

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study implements a two-site screening program using the CUORE and FINDRISC tools to identify adults aged 50 with potential T2DM or CVD risk. Data are collected at local prevention departments with point-of-care measurements, including finger-prick HbA1c and lipid panels. Recruitment is by invitation letters, with informed consent and training for healthcare staff to ensure standardized data collection. The trial runs through 2026 and focuses on feasibility and system integration within the regional health authority.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Citizens resident in Ascoli Piceno province
* People turning 50 in 2026
* Capacity to consent
* Fulfilling and signing the informed consent related to the participation to the study.

Exclusion Criteria:

* a concomitant diagnosis of DM and a previous CVD major event (one or more between Myocardial infarction, Haemorrhagic and/or ischaemic stroke, Revascularization interventions, as percutaneous coronary intervention/coronary artery bypass graft)
* Failure to meet the inclusion criteria
* Lack of written informed consent.

Where it's running

• Prevention Department of Ascoli Piceno Province
  Ascoli Piceno, Ascoli Piceno, Italy Recruiting
• Prevention Department of Ascoli Piceno Province
  San Benedetto del Tronto, Ascoli Piceno, Italy Recruiting

Study contacts

• Principal investigator: Claudio CA Angelini — Local Health Authority of Ascoli Piceno
• Study coordinator: Claudio CA Angelini
• Email: claudio.angelini@sanita.marche.it
• Phone: +39 0736-358016

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-based prediction of five major diseases using integrated health data

  Researchers are testing an AI model to see if they can predict the onset of five major diseases in adults 30–65 by combining medical records with biospecimens and lifestyle data.

  Recruiting Asan Medical Center · Seoul, Seoul Special City · NCT07595718

• Vicadrostat with empagliflozin for people with type 2 diabetes, high blood pressure, and heart disease

  This trial will test whether adding vicadrostat to empagliflozin lowers cardiovascular risk in adults who have type 2 diabetes, high blood pressure, and existing cardiovascular disease but no history of heart failure.

  Recruiting at 1096 sites Phase 3 Boehringer Ingelheim · Anniston, Alabama and 1141 other locations · NCT07064473

• Kefir for vascular and immune health in people with or at risk for type 2 diabetes

  This 12-week test will see if drinking 350 mL of traditional kefir each day helps improve blood vessel and immune health in adults aged 24–70 who have or are at higher risk for type 2 diabetes.

  Recruiting University of Alberta · Edmonton, Alberta · NCT06695221

• Evaluating human placental membrane products for treating nonhealing diabetic foot and venous leg ulcers

  This study is testing whether using human placental products along with regular care can help people with stubborn diabetic foot and leg ulcers heal better.

  Recruiting C5 Biomedical · Metairie, Louisiana · NCT06674980

• Evaluating Enavogliflozin for Heart and Kidney Health in Type 2 Diabetes

  This study is testing if a new diabetes medication called enavogliflozin can improve heart and kidney health in adults with type 2 diabetes compared to other similar medications.

  Recruiting Phase 4 Yonsei University · Seoul · NCT06642623

• Using a genetic test to manage heart and kidney complications in type 2 diabetes

  This study is testing if a genetic test can help doctors better manage heart and kidney problems in people with type 2 diabetes by personalizing their treatment based on their genetic risk.

  Recruiting Optithera · Montreal, Quebec and 1 other locations · NCT06586203

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.